Company DescriptionLeap Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. The company operates in the biopharmaceutical sector, specializing in the research and development of novel therapeutics aimed at treating various types of cancer. Leap Therapeutics is dedicated to advancing its lead product candidates, which target key pathways in cancer biology to provide new treatment options for patients.

How the Company Makes MoneyLeap Therapeutics makes money primarily through the development and commercialization of its proprietary cancer treatment therapies. The company generates revenue through strategic partnerships, licensing agreements, and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of successfully developed products. Leap Therapeutics may also secure funding through public and private investments to support its research and development activities.

Cypherpunk Technologies Financial Statement Overview

Summary

Leap Therapeutics is facing financial challenges with ongoing losses, negative cash flows, and zero revenue growth. While the low debt levels and stable equity ratio are positives, the lack of revenue and continuous cash burn are major concerns. Strategic changes are necessary for sustainable growth.

Income Statement

Leap Therapeutics has consistently reported zero revenue from 2021 to 2024 following a marginal revenue in 2020. The net income has been negative throughout, indicating persistent losses. EBIT and EBITDA margins are also negative, showcasing an ongoing struggle in generating profits.

Balance Sheet

The company's debt levels are low relative to equity, resulting in a low debt-to-equity ratio, which is a positive indicator. However, the continuous erosion of shareholder equity due to losses is concerning. The equity ratio remains stable, suggesting adequate asset coverage by equity.

Cash Flow

Operating cash flow is consistently negative, reflecting cash burn from operations. Free cash flow has also been negative, though there was a significant financing inflow in 2021. The company has not shown growth in free cash flow, indicating financial strain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	443.00K	0.00	0.00	0.00	1.50M	10.05M
Gross Profit	-30.57M	0.00	-427.00K	0.00	1.50M	5.12M
EBITDA	-77.44M	-70.05M	-80.99M	-54.38M	-40.54M	-3.23M
Net Income	-98.22M	-67.56M	-81.41M	-54.60M	-40.59M	-3.39M
Balance Sheet
Total Assets	294.82M	49.12M	72.83M	58.09M	117.91M	70.42M
Cash, Cash Equivalents and Short-Term Investments	174.14M	47.25M	70.64M	43.76M	114.92M	63.83M
Total Debt	3.31M	266.00K	262.00K	524.00K	469.00K	776.00K
Total Liabilities	52.61M	14.08M	12.68M	3.45M	10.02M	3.01M
Stockholders Equity	242.22M	35.05M	60.14M	54.64M	107.89M	67.41M
Cash Flow
Free Cash Flow	-62.76M	-60.30M	-43.75M	-49.04M	-35.16M	-25.96M
Operating Cash Flow	-60.77M	-60.30M	-43.75M	-49.04M	-35.16M	-25.96M
Investing Cash Flow	13.99M	0.00	48.97M	0.00	0.00	25.00K
Financing Cash Flow	137.00K	37.18M	-30.00K	-210.00K	98.03M	74.00M

Cypherpunk Technologies Technical Analysis

Technical Analysis Sentiment

Last Price―

Price Trends

50DMA

100DMA

200DMA

Market Momentum

MACD

RSI

STOCH

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYPH, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for CYPH.

Cypherpunk Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―